Temozolomide

primary CNS, you're still doing the high-dose methotrexate protocol?

Yeah, we do the high-dose methotrexate usually with Temodar and rituximab, though.

I've been impressed that the Europeans use this matrix regimen with Zyotepa and Cytarabine that I think we've been very afraid of.

But in talking to the investigators over there, they very quickly dropped the dose of the Cytarabine, and the Cytarabine's what drives the toxicity there.

So I think that, you know, I've been sort of convinced over time that you need more than just high-dose methotrexate for many of these patients.

And the Temodar, I think, we use a lot of that regimen.

But I think there is, Citerabine is such a good lymphoma drug that I think it may have a role there.

Well, love to have more time, but we're out.

I knew I needed to start my standard of care.

I, you know, I'm unmethylated, so I wasn't going to do the TMZ, but I needed to start radiotherapy.

And so like, it's been five weeks, it's been six weeks, I haven't started yet.

My oncologist is like- That

Me dijeron una y otra vez que sin la quimioterapia morira, denuncia.

Jones cont que cuando era joven, el profesor Ian Brown, un mdico del Hospital Universitario de Coventry, en el centro de Inglaterra, le dijo que tendra que tomar el efrmaco de quimioterapia temozolomide, TMZ, durante el resto de su vida.

Jones told him that when he was young, Professor Ian Brown, a doctor at Coventry University Hospital in central England, told him that he would have to take the chemotherapy temozolomide, TMZ, for the rest of his life.

Temozolomide chemotherapy, TMZ, for the rest of his life.

Jones cont que cuando era joven, el profesor Ian Brown, un mdico del Hospital Universitario de Coventry, en el centro de Inglaterra, le dijo que tendra que tomar el efrmaco de quimioterapia temozolomide, TMZ, durante el resto de su vida.

Final de mes ledas.

Esto ocurre a pesar de que las directrices recomiendan seis ciclos en un periodo de seis meses.

The report concluded that the hospital staff's mistakes amounted to a betrayal of patients' trust and also a question: why? The oncol-- pharmacy teams did not ask patients who were receiving oral chemotherapy on an ongoing basis for ten to fifteen years o-s.